Natco Pharma Ltd shares fall 1.45% as disclosure of investment in eGenesis, Inc.
Why did Natco Pharma Ltd shares fall today?
Shares of Natco Pharma Ltd fell by 1.45% today, reaching ₹870.65 as of 12:45 PM on Tuesday. This decline followed a disclosure made by the company under SEBI regulations regarding its investment in eGenesis, Inc., which may have influenced investor sentiment.
In a press release dated August 25th, 2026, Natco Pharma Limited announced it is investing US$ 14 million in eGenesis, Inc. through its wholly owned subsidiaries. Specifically, NATCO Pharma (Canada) Inc. contributed US$ 9.5 million, while NATCO Pharma South Africa Proprietary Limited invested US$ 4.5 million. These investments were made via convertible promissory notes, a financial instrument that can later convert into equity.
This new investment adds to a prior US$ 8 million investment made by Natco in eGenesis in 2024 through preferred stock, bringing the total investment to US$ 22 million. The disclosure was submitted to stock exchanges as required by listing regulations, providing transparency about the company’s financial moves. While the announcement itself details the investment, the share price drop suggests market reactions to this news or broader factors.
What does Natco Pharma Ltd do?
Natco Pharma Limited is an entity listed on the BSE and NSE stock exchanges in India. The company is making an investment of US$ 14 million in eGenesis, Inc. This investment is being executed through the company's wholly owned subsidiaries.
The investment is divided between two subsidiaries: NATCO Pharma (Canada) Inc. is contributing US$ 9.5 million, and NATCO Pharma South Africa Proprietary is contributing the remainder.
Natco Pharma Ltd Financials
In CroresNatco Pharma Ltd demonstrated significant financial growth between the December 2025 and March 2026 quarters. The company's revenue increased from ₹647.3 Crores to ₹739.1 Crores, while its profit saw a sharp rise from ₹151.5 Crores to ₹267.9 Crores. This data reflects a clear upward trend in both top-line and bottom-line performance over the observed period.
Natco Pharma Ltd Shareholding Pattern
Promoter holding stands at 49.41% of the total share capital. Foreign Institutional Investors (FIIs) hold 16.99% stake in the company, while Domestic Institutional Investors (DIIs) hold 5.63%. Public shareholders hold the remaining 27.97% stake in Natco Pharma Ltd.
Natco Pharma Ltd FAQs
Q: Why did Natco shares fall 1.45% today?
Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Natco Pharma Ltd?
As per the latest data, promoters hold 49.41% stake in Natco Pharma Ltd, while FII holding stands at 16.99%. Domestic institutional investors hold 5.63%, and public shareholders account for 27.97% of the equity.
Q: What is the current stock price of Natco Pharma Ltd?
Natco Pharma Ltd shares are currently trading at ₹870.65, recording a decline of 1.45% from the previous close.
Q: What is the market capitalization of Natco Pharma Ltd?
The company currently has a market capitalization of ₹15594.2 crore, reflecting its valuation in the Indian equity market.